Medpace Holdings, Inc. (MEDP) Revenue by Segment & Business Profile
Oncology was 32.1% of Medpace Holdings, Inc.'s revenue across the 6 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-09-30 · read by EquiReason
MEDPMedpace Holdings, Inc.Follow MEDP — free
—
Price chart with a free account
- Market cap
- 18.7B
- P/E TTM
- 37.2
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 8 Feb, in 107 days
What the company does
Medpace Holdings, Inc. is a diagnostics & research company in the healthcare sector. In its SEC filings it reports 6 business lines: Oncology (32%), Metabolic (29%), Other (14%), Central Nervous System (12%) and others. Trailing twelve-month revenue: $2.8 billion as of 2026-09-30.
Roles we read
from the filings, not the sector label- Drug discovery / CRO
Medpace Holdings, Inc. — questions
- What does Medpace Holdings, Inc. do?
- Medpace Holdings, Inc. is a diagnostics & research company in the healthcare sector. In its SEC filings it reports 6 business lines: Oncology (32%), Metabolic (29%), Other (14%), Central Nervous System (12%) and others. Trailing twelve-month revenue: $2.8 billion as of 2026-09-30.
- How does Medpace Holdings, Inc. make money?
- By the lines it reports in its SEC filings: Oncology 32.1%, Metabolic 29.2%, Other 14.0%, Central Nervous System 11.7%, Cardiology 8.6% of revenue.
Every figure on this page comes from Medpace Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.